Stefan Garczyk

Aachen, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Multidimensional OMICs reveal ARID1A orchestrated control of DNA damage, splicing, and cell cycle in normal-like and malignant urothelial cells.

Multidimensional OMICs reveal ARID1A orchestrated control of DNA damage, splicing, and cell cycle in normal-like and malignant urothelial cells.

Journal: Molecular oncology

Published: August 28, 2024

Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer.

Heterogenous NECTIN4 expression in urothelial high-risk non-muscle-invasive bladder cancer.

Journal: Virchows Archiv : an international journal of pathology

Published: November 12, 2021

Molecular Characterization of Muellerian Tumors of the Urinary Tract.

Molecular Characterization of Muellerian Tumors of the Urinary Tract.

Journal: Genes

Published: May 04, 2021

Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.

Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer.

Journal: Virchows Archiv : an international journal of pathology

Published: November 13, 2020

SWI/SNF Alterations in Squamous Bladder Cancers.

SWI/SNF Alterations in Squamous Bladder Cancers.

Journal: Genes

Published: October 14, 2020

Pure high-grade papillary urothelial bladder cancer: a luminal-like subgroup with potential for targeted therapy.

Pure high-grade papillary urothelial bladder cancer: a luminal-like subgroup with potential for targeted therapy.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: December 17, 2019

Comparative genomic profiling of glandular bladder tumours.

Comparative genomic profiling of glandular bladder tumours.

Journal: Virchows Archiv : an international journal of pathology

Published: December 10, 2019

Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder.

Next-Generation Sequencing Reveals Potential Predictive Biomarkers and Targets of Therapy for Urothelial Carcinoma in Situ of the Urinary Bladder.

Journal: The American journal of pathology

Published: June 28, 2019

ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?

ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?

Journal: PloS one

Published: May 07, 2018

Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications.

Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications.

Journal: Virchows Archiv : an international journal of pathology

Published: January 11, 2018

Oncogenic features of neuromedin U in breast cancer are associated with NMUR2 expression involving crosstalk with members of the WNT signaling pathway.

Oncogenic features of neuromedin U in breast cancer are associated with NMUR2 expression involving crosstalk with members of the WNT signaling pathway.

Journal: Oncotarget

Published: December 20, 2016

Loss of Dickkopf 3 Promotes the Tumorigenesis of Basal Breast Cancer.

Loss of Dickkopf 3 Promotes the Tumorigenesis of Basal Breast Cancer.

Journal: PloS one

Published: May 18, 2016

Showing 1-12 of 13

Last Updated: 09/26/2026